Comparison of outcome measures from a trial of Mycophenolate mofetil in myasthenia gravis
- 23 October 2008
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 38 (5), 1429-1433
- https://doi.org/10.1002/mus.21142
Abstract
We determined the strength of correlation among, and responsiveness of, outcome measures used in a multicenter, double‐blind, placebo‐controlled trial of mycophenolate mofetil in combination with prednisone in myasthenia gravis (MG). The primary efficacy measure was the change from baseline in the Quantitative MG (QMG) score at week 12. Secondary outcome measures included the MG—Activities of Daily Living profile (MG‐ADL) and MG Manual Muscle Test (MMT). The measures were collected at baseline and at weeks 4, 8, and 12 in the blinded study and at weeks 16, 20, 28, and 36 in an optional open‐label extension. At baseline, the QMG was moderately correlated with the MG‐ADL (r = 0.55, P < 0.0001) and the MMT (r = 0.53, P < 0.0001), but the correlation between the MG‐ADL and the MMT was lower (r = 0.30, P = 0.007). These findings were similar at weeks 4, 8, and 12. Similar correlations were found among the changes in scores from baseline at weeks 12 and 36. The MMT and MG‐ADL appeared to be the most sensitive measures for changes in MG status at weeks 12 and 36. Although a task force has recommended use of the QMG in prospective MG trials, the MMT and MG‐ADL appear to be suitable alternatives and offer potential advantages. No special training or equipment is required, and they take less time. © 2008 Wiley Periodicals, Inc. Muscle Nerve 38: 1429–1433, 2008Funding Information
- Orphan Products Development Program of the U.S. FDA (FD-R-002154))
- F. Hoffmann-La Roche, Ltd. (Roche) (CEL248))
- Aspreva Pharmaceuticals
- General Clinical Research Center (GCRC) of the National Center for Research Resources
- NIH (MO1-RR00034, M01-RR00044, M01-RR01346, M01-RR023940)
This publication has 18 references indexed in Scilit:
- A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravisNeurology, 2008
- Issues in SMA clinical trial design: The International Coordinating Committee (ICC) for SMA Subcommittee on SMA Clinical Trial DesignNeuromuscular Disorders, 2007
- Excellent inter‐rater, intra‐rater, and telephone‐administered reliability of the ALSFRS‐R in a multicenter clinical trialAmyotrophic Lateral Sclerosis, 2007
- Quantitative myasthenia gravis score: Assessment of responsiveness and longitudinal validityNeurology, 2005
- Mycophenolate mofetil for myasthenia gravisNeurology, 2003
- Standards of Measurements in Myasthenia GravisAnnals of the New York Academy of Sciences, 2003
- Reliability of 4 Outcome Measures in Pediatric Spinal Muscular AtrophyArchives of Neurology, 2003
- Myasthenia gravisNeurology, 2000
- Reliability Testing of the Quantitative Myasthenia Gravis ScoreaAnnals of the New York Academy of Sciences, 1998
- Measuring change over time: Assessing the usefulness of evaluative instrumentsJournal of Chronic Diseases, 1987